Czech Republic swoops for Denmark’s 2.4m unwanted AZ COVID shotsThe Czech Republic wants to buy around 2.4 million doses of the AstraZeneca/Oxford University vaccine ditched by Denmark, Share XCzech Republic swoops for Denmark’s 2.4m unwanted AZ COVID shotshttps://pharmaphorum.com/news/czech-republic-swoops-for-denmarks-2-4m-unwanted-az-covid-shots/
England begins Moderna vaccine rollout as lockdown easesEngland is beginning its rollout of the Moderna COVID-19 vaccine, offering an alternative to the AstraZeneca/Oxford University jab Share XEngland begins Moderna vaccine rollout as lockdown easeshttps://pharmaphorum.com/news/england-begins-moderna-vaccine-rollout-as-lockdown-eases/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Provention faces delay in FDA review of diabetes prevention antibodyThe FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for Share XProvention faces delay in FDA review of diabetes prevention antibodyhttps://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
Acadia puts blame on FDA as Nuplazid rejected for dementiaAcadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Share XAcadia puts blame on FDA as Nuplazid rejected for dementiahttps://pharmaphorum.com/news/acadia-blame-fda-nuplazid-rejected-dementia/
NICE backs Sobi’s Kineret for rare inflammatory diseaseThe UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Share XNICE backs Sobi’s Kineret for rare inflammatory diseasehttps://pharmaphorum.com/news/nice-backs-sobis-kineret-for-rare-inflammatory-disease/
Germany and Canada restrict AZ vaccine over blood clot fearsGermany and Canada have both slapped restrictions on the AstraZeneca vaccine, recommending its use only in older patients, Share XGermany and Canada restrict AZ vaccine over blood clot fearshttps://pharmaphorum.com/news/germany-and-canada-restrict-az-vaccine-again-over-blood-clot-fears/
World leaders call for international pandemic preparedness treatyMore than 20 world leaders have called for an international treaty for pandemic preparedness to protect the world Share XWorld leaders call for international pandemic preparedness treatyhttps://pharmaphorum.com/news/world-leaders-call-for-international-pandemic-preparedness-treaty/
Moderna COVID-19 shot available in UK next monthThe Moderna COVID-19 vaccine will be added to the UK’s arsenal of coronavirus vaccines in April, when the Share XModerna COVID-19 shot available in UK next monthhttps://pharmaphorum.com/news/moderna-coronavirus-shot-available-in-uk-next-month/
CHMP backs Celltrion’s regdanvimab antibody for COVID-19The EU looks set to approve emergency use of a third antibody therapy for COVID-19 after its human Share XCHMP backs Celltrion’s regdanvimab antibody for COVID-19https://pharmaphorum.com/news/chmp-backs-celltrions-regdanvimab-antibody-for-covid-19/
EU stops short of vaccine export controls after summitThe European Union has stopped short of export controls on vaccines after leaders met at a summit to Share XEU stops short of vaccine export controls after summithttps://pharmaphorum.com/news/eu-stops-short-of-vaccine-export-controls-after-summit/
Boris Johnson slammed for saying ‘greed’ is behind UK vaccine successBoris Johnson’s sense of humour seems to have got him into trouble again, at the most delicate of Share XBoris Johnson slammed for saying ‘greed’ is behind UK vaccine successhttps://pharmaphorum.com/news/boris-johnson-slammed-for-saying-greed-is-behind-uk-vaccine-success/
EU on brink of ‘vaccine war’ as AZ shot shines in US trialWith its vaccine roll-out in chaos after last week’s safety alert, Europe is reportedly on the brink of Share XEU on brink of ‘vaccine war’ as AZ shot shines in US trialhttps://pharmaphorum.com/news/eu-on-brink-of-vaccine-war-as-az-shot-shines-in-us-trial/
NICE backs ovarian cancer and multiple myeloma combination drugsNICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft Share XNICE backs ovarian cancer and multiple myeloma combination drugshttps://pharmaphorum.com/news/nice-backs-ovarian-cancer-and-multiple-myeloma-combination-drugs/
NICE axes funding for MSD’s Keytruda in bladder cancer despite appealNICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal Share XNICE axes funding for MSD’s Keytruda in bladder cancer despite appealhttps://pharmaphorum.com/news/nice-axes-funding-for-msds-keytruda-in-bladder-cancer-despite-appeal/
NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
Novartis says £1.8m Zolgensma is model for gene therapy pricingNovartis has said its gene therapy pricing model, involving a steep one-off payment, could be a template for Share XNovartis says £1.8m Zolgensma is model for gene therapy pricinghttps://pharmaphorum.com/news/novartis-e1-9m-zolgensma-is/
